Title : Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?

Pub. Date : 2015 Jul

PMID : 26126090






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The vasopressin inhibitor tolvaptan is clinically effective in slowing growth of renal cysts and reduction in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD), but these effects are mitigated by the associated polyuria. Tolvaptan arginine vasopressin Homo sapiens